Author: Editor

Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here: https://meetinglibrary.asco.org/record/186053/abstract

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO.

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO. More here: https://www.strataoncology.com/asco20

Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and predicted impact on actionable biomarker identification vs. hybrid capture (H)-CGP and plasma (P)-CGP presented at this year’s virtual ASCO. More here: https://www.strataoncology.com/asco20

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7550?af=R&

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7550?af=R&

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract

Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.

Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM). Read here: https://meetinglibrary.asco.org/record/186864/abstract

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM.

Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM. Read here: https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-a-new-subcutaneous-formulation-of-daratumumab-in-the-treatment-of-patients-with-multiple-myeloma-301051154.html

Saad Z. Usmani, M.D of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM. Read here: https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-a-new-subcutaneous-formulation-of-daratumumab-in-the-treatment-of-patients-with-multiple-myeloma-301051154.html

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab forpreviously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Earn CME: https://www.naccme.com/program/20-hemcovid-6 In this webcast, Drs. Joseph R. Mikhael and Jessica K. Altman discuss best practices for addressing current and potential challenges in the diagnosis and management of myeloid malignancies during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-5 In this webcast, Dr. Joseph R. Mikhael and patient advocate Yelak Biru discuss ways to limit patient and provider exposure to SARS-CoV-2 while effectively managing hematologic malignancies © 2020 Imedex, an HMP Company

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.

Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade treatment. Read here: https://www.eurekalert.org/pub_releases/2020-04/c-ktt042720.php

Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade treatment. Read here: https://www.eurekalert.org/pub_releases/2020-04/c-ktt042720.php

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Read here: https://meetinglibrary.asco.org/record/186845/abstract

Andrew Krivoshik, MD of Astellas @AstellasUS discusses what is net for Astellas.

Andrew Krivoshik, MD of Astellas @AstellasUS discusses the long-term results of the phase III ADMIRAL trial presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185308/abstract

Andrew Krivoshik, MD of Astellas @AstellasUS discusses the importance of the phase III PROSPER trial in the prostate cancer community presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/187453/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment in older patients with AML presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/185292/abstract

Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO. ______________ Results from the Phase 2 Pevonedistat-2001 trial will be presented in an oral session at ASCO. The study investigated pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes (HR-MDS), higher-risk chronic myelomonocytic leukemia (HR-CMML) or low blast acute myeloid leukemia (LB-AML).These patients typically have poor prognoses as a result of limited response to available therapies. HR-MDS, in particular, has…

Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO. ______________ Results from the Phase 2 Pevonedistat-2001 trial will be presented in an oral session at ASCO. The study investigated pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes (HR-MDS), higher-risk chronic myelomonocytic leukemia (HR-CMML) or low blast acute myeloid leukemia (LB-AML).These patients typically have poor prognoses as a result of limited response to available therapies. HR-MDS, in particular, has…

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced non-small cell lung cancer harboring exon 20 insertion mutations. Read here: https://meetinglibrary.asco.org/record/184802/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract

Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results. Read here: https://meetinglibrary.asco.org/record/187437/abstract